We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat the global COVID-19 health crisis. Given the growing global need for an effective, safe antiviral treatment, we are advancing multiple antiviral therapeutic candidates targeting SARS-CoV-2 as quickly and efficiently as possible, while also advancing the discovery and development of antiviral compounds for other high-value indications.

Nasdaq Bell Ringing Ceremony